argenx NV ADR (ARGX)vsNervGen Pharma Corp. (NGEN)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
NGEN
NervGen Pharma Corp.
$1.44
-4.00%
HEALTHCARE · Cap: $153.76M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
NGEN
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Intrinsic value data unavailable for NGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : NGEN
NGEN has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : NGEN
The primary concerns for NGEN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while NGEN is a value play — different risk/reward profiles.
NGEN carries more volatility with a beta of 0.82 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 16/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
NervGen Pharma Corp. (NGEN) is an innovative biotechnology company dedicated to addressing critical unmet medical needs in neurodegenerative diseases with its proprietary nerve regeneration technology platform. The company focuses on developing groundbreaking therapeutics that aim to restore nerve function in conditions such as multiple sclerosis and spinal cord injuries. By advancing its clinical trials and expanding its intellectual property portfolio, NervGen is strategically positioned to capitalize on the growing demand for effective neurological treatments, presenting substantial growth potential and value creation opportunities for institutional investors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?